BIOMAT Database Logo BIOMAT Database Logo

Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. 1991

E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Drug Targeting Laboratory, Institute of Cancer Research, Sutton, England.

An immunotoxin consisting of ricin A chain linked to the monoclonal antibody M-T151, recognising the CD4 antigen, was weakly toxic to the human T-lymphoblastoid cell line CEM in tissue culture. The incorporation of [3H]leucine by CEM cells was inhibited by 50% at an M-T151--ricin-A-chain concentration (IC50) of 4.6 nM compared with an IC50 of 1.0 pM for ricin. In contrast, immunotoxins made by linking intact ricin to M-T151 in such a way that the galactose-binding sites of the B chain subunit were either blocked sterically by the antibody component or were left unblocked, were both powerfully cytotoxic with IC50 values of 20-30 pM. The addition of ricin B chain to CEM cells treated with M-T151--ricin-A-chain enhanced cytotoxicity by only eight-fold indicating that isolated B chain potentiated the action of the A chain less effectively than it did as an integral component of an intact ricin immunotoxin. Ricin B chain linked to goat anti-(mouse immunoglobulin) also potentiated weakly. Lactose completely inhibited the ability of isolated ricin B chain to potentiate the cytotoxicity of M-T151--ricin-A-chain and partially (3- to 4-fold) inhibited the cytotoxicity of the blocked and non-blocked ricin immunotoxins. Thus, in this system, the galactose-binding sites of the B chain contributed to cell killing regardless of whether isolated B chain was associated with the A chain immunotoxin or was present in blocked or non-blocked form as part of an intact ricin immunotoxin. The findings suggest that the blocked ricin immunotoxin may become unblocked after binding to the target antigen to re-expose the cryptic galactose-binding sites. However, the unblocking cannot be complete because the maximal inhibition of [3H]leucine incorporation by the blocked immunotoxin was only 80% compared with greater than 99% inhibition by the non-blocked immunotoxin.

UI MeSH Term Description Entries
D007785 Lactose A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. Anhydrous Lactose,Lactose, Anhydrous
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005690 Galactose An aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins. Deficiency of galactosyl-1-phosphate uridyltransferase (GALACTOSE-1-PHOSPHATE URIDYL-TRANSFERASE DEFICIENCY DISEASE) causes an error in galactose metabolism called GALACTOSEMIA, resulting in elevations of galactose in the blood. D-Galactose,Galactopyranose,Galactopyranoside,D Galactose
D006041 Goats Any of numerous agile, hollow-horned RUMINANTS of the genus Capra, in the family Bovidae, closely related to the SHEEP. Capra,Capras,Goat
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain.
July 1984, The Journal of experimental medicine,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Immunotoxins containing ricin or its A chain.
February 1991, Seminars in cell biology,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain.
January 1991, International journal of cancer,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain.
August 1996, FEBS letters,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
January 1988, Cancer immunology, immunotherapy : CII,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells.
October 1983, Proceedings of the National Academy of Sciences of the United States of America,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Ricin B chain converts a non-cytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agent.
November 1983, FEBS letters,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
[Comparison of cytotoxic properties of immunotoxins with the ricin A chain against differentiated antigens from human T-lymphocytes].
January 1994, Doklady Akademii nauk,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
January 1992, Cancer immunology, immunotherapy : CII,
E J Wawrzynczak, and G J Watson, and A J Cumber, and R V Henry, and G D Parnell, and E P Rieber, and P E Thorpe
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
July 1993, International journal of cancer,
Copied contents to your clipboard!